Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Non-Current Receivables: 2009-2022

Historic Non-Current Receivables for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Sep 2022 value amounting to $1.1 million.

  • Avadel Pharmaceuticals' Non-Current Receivables rose 18.31% to $1.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.1 million, marking a year-over-year increase of 18.31%. This contributed to the annual value of $1.2 million for FY2021, which is 64.44% down from last year.
  • As of Q3 2022, Avadel Pharmaceuticals' Non-Current Receivables stood at $1.1 million, which was down 4.21% from $1.2 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' 5-year Non-Current Receivables high stood at $7.8 million for Q2 2019, and its period low was $961,000 during Q3 2021.
  • Moreover, its 3-year median value for Non-Current Receivables was $1.2 million (2022), whereas its average is $2.7 million.
  • As far as peak fluctuations go, Avadel Pharmaceuticals' Non-Current Receivables spiked by 146.37% in 2018, and later plummeted by 84.66% in 2021.
  • Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Non-Current Receivables stood at $7.3 million in 2018, then decreased by 13.06% to $6.3 million in 2019, then crashed by 45.51% to $3.4 million in 2020, then slumped by 64.44% to $1.2 million in 2021, then rose by 18.31% to $1.1 million in 2022.
  • Its Non-Current Receivables stands at $1.1 million for Q3 2022, versus $1.2 million for Q2 2022 and $1.2 million for Q1 2022.